<DOC>
	<DOCNO>NCT00476619</DOCNO>
	<brief_summary>Full Title : A Randomized Controlled Trial Procrit Prevention Acute Renal Failure Patients Receiving Intravenous Contrast Primary Objective : To evaluate efficacy one-time dose intravenous erythropoietin administration prevention attenuation contrast-induced acute renal failure . Secondary Objectives : To evaluate serum urinary marker renal injury , include KIM-1 , BMP-7 , TGF-b , along biomarkers , subject receive intravenous contrast correlate expression clinical outcome Study Design : Prospective , multi-centered , randomize , double blind , placebo control trial one-time dose EPO . Subjects follow seven day hospital discharge , whichever longer . Total estimate study duration 3 year .</brief_summary>
	<brief_title>Erythropoietin Radiocontrast Induced Nephropathy ( ERIN ) Trial</brief_title>
	<detailed_description>Adult subject without diabetes mellitus Eligibility Criteria : undergoing intravenous contrast administration computerize axial tomography ( CAT Scan ) inpatient . Subjects exclude end-stage renal disease ( dialysis peritoneal dialysis ) ; know history acute renal failure ; hemoglobin ³ 12.0 g/dL ; history use erythropoietin replacement transfusion within prior 3 day ; use Glucophage/Metformin Glucovance ; unable give write informed consent ; hemodynamic instability ; uncontrolled hypertension ; history current malignancy , current malignancy define subject undergoing treatment chemotherapy radiation therapy , subject know metastatic disease , terminal malignant disease ; history MI , CVA , active angina unstable angina within past three month ; pregnant lactating ; allergic intravenous contrast , iodine , erythropoietin , mammalian-cell derived product , human albumin ; patient seizure disorder CT scan do hospital outpatient .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Subjects age 18 either gender . 2 . Scheduled receive CT scan intravenous contrast dye . 3 . Non diabetic subject type 1 2 diabetes mellitus 4 . Written informed consent . 5 . Subjects diuretic nonsteroidal inflammatory agent exclude . 6 . Subjects receive nacetylcysteine sodium bicarbonate pre CT scan exclude 1 . Pregnant lactating woman . 2 . Endstage renal disease ( hemodialysis peritoneal dialysis ) 3 . A known history acute renal failure 4 . Subjects receive glucophage/metformin glucovance 5 . Subjects give write informed consent . 6 . Subjects receive peritoneal dialysis hemodialysis . 7 . Subjects enrol another investigational drug study ≤ 30 day enrollment present study . 8 . Subjects know hypersensitivity anaphylaxis contrast dye iodine . 9 . Subjects know hypersensitivity anaphylaxis erythropoietin , mammaliancell derive product , human albumin . 10 . Age &lt; 18 year 11 . Use erythropoietin replacement transfusion within prior 3 day 12 . Baseline Hemoglobin &gt; 12.0 g/dL 13 . Uncontrolled hypertension , systolic BP &gt; 180 mmHg diastolic BP &gt; 110 mmHg record past 24 hour . 14 . Evidence hemodynamic instability 15 . Subject unable follow protocol due mental incompetence reason 16 . Inaccessibility medical record 17 . Subjects history MI , CVA , active angina unstable angina within past three month 18 . Subjects history current malignancy , current malignancy define subject undergoing treatment chemotherapy radiation therapy , subject know metastatic disease , terminal malignant disease . 19 . Subject known history seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Contrast</keyword>
	<keyword>Nephropathy</keyword>
	<keyword>acute renal failure</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>CT scan</keyword>
</DOC>